Global In Situ Hybridization Market - 2023-2030

Global In Situ Hybridization Market - 2023-2030

Market Overview
The global In Situ Hybridization market reached US$ 9700.40 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15087.46 million by 2030. The market is growing at a CAGR of 11.9% during the forecast period (2023-2030).

In situ hybridization (ISH) uses a labeled complementary DNA, RNA, or modified nucleic acid strand (i.e., probe) to localize a particular DNA or RNA sequence in a portion or section of tissue, or if the tissue is small enough, in the entire tissue (e.g., plant seeds, Drosophila embryos), in cells, and in circulating tumor cells (CTCs). Immunohistochemistry, which often localizes proteins in tissue slices, is different from this.

Market Dynamics
The Increasing incidence of Cancer cases
Smoking and poor eating habits are to responsible for the increase in cancer occurrences. That is a significant growth factor for the ISH market. For instance, the WHO reports that cancer will be the top cause of mortality globally in 2020, accounting for around 10 million deaths, or roughly one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.

In low- and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases. And as a result, in-situ hybridization demand is increasing during the anticipated period.

The Lack of trained personnel will hamper the market.
To carry out an ISH-based test, one needs to be aware of the molecular specifics of a chromosome or gene. Resistance to the transition from manual to automated procedures is another barrier to the industry's growth. Too many suppliers, making the transfer from manual or antiquated processes to IT-based ones is challenging, if not impossible. Because of this, the broad use of ISH-based diagnosis is limited, particularly in developing countries, by a lack of qualified, educated, and technically adept laboratory personnel.

Segment Analysis
The global In Situ Hybridization market is segmented based on product, technology, application, end user,and region.
On basis of the technology, FISH isexpected to hold the largest share
The FISH segment is expected to hold the largest share in the In Situ Hybridization market owing to the increasing number oforthopedic surgeries across the globe. For instance, a chromosome from a person is attached to a glass slide using the Fluorescence In Situ Hybridization (FISH) laboratory procedure, which exposes the chromosome to a probe made of purified DNA that has been fluorescently dyed. It is used to diagnose cancer, chromosomal abnormalities, gene mapping, and genetic illnesses. Growing genetic problems, chronic diseases, and rising demand for effective diagnostic methods are factors in the expansion of the FISH segment. And when more products are released by different market players, the market expands as a result of the rising demand for FISH methods.

For instance, in May 2021, as a part of its newly launched Vizgen release program, Vizgen launched its publicly accessible data collection. The precise location of transcripts from 483 genes can be found in the open-source spatial genomics dataset known as the Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map. Therefore, the above-mentioned factors help the FISH segment to dominate the market.

Geographical Penetration
Rising higher rates of infectious diseases, genetic abnormalities drives the region
North America’sIn Situ Hybridization market is anticipated to grow in the forecast period owing to increasing product launches by the key players in the region. For instance, because to the region's higher rates of infectious diseases, genetic abnormalities, and cancer, North America is anticipated to hold the majority of the market share for in situ hybridization. The market is also anticipated to increase as a result of increasing research and development efforts, the existence of major industry competitors, and regular product debuts. For instance, estimated numbers of new cancer cases and fatalities in 2022, according of the American Cancer Society (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). The 2022 year special section examines the prevalence of cancer risk factors and screening among American Indian and Alaska Native (AIAN) people.

Competitive Landscape
The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.

COVID-19 Impact Analysis
By Product
• Consumables
• Instruments
• Software
By Technology
• FISH
DNA FISH
RNA FISH
PNA FISH
• CISH
By Application
• Cancer Diagnostics
• Cytology
• Infectious Disease Diagnostics
• Neuroscience
• Immunology
By End User
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract research organizations
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Russia
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In April 6, 2021, A strategic business relationship between Applied Spectral Imaging (ASI) and KromaTiD, Inc. has been announced. Under this partnership, ASI will have the exclusive worldwide rights to offer Pinpoint FISH (PPF) probes and test services developed by KromaTiD.
• In March 10, 2020, an Improved FISH Probe is Introduced by Creative Bioarray to Identify 2019 New Coronavirus. Viral particles in infected cells can be recognized using in site hybridization (ISH), which also offers precise molecular identification and visualization of infected cell types and regions.
• On May 26, 2020, The CE-IVD designated RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform has been made available in Europe by Leica Biosystems and Bio-Techne. Leica's platform and Bio-RNAscope Techne will give pathologists access to the top applications to help their diagnostics labs.

Why Purchase the Report?
• To visualize the global In Situ Hybridization- market segmentation based on product, technology, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of In Situ Hybridization market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global In Situ Hybridization market report would provide approximately 61 tables, 58 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies